Abstract:James P Franciosi, 1, 2 Edward B Mougey, 3 Evan S Dellon, 4 Carolina Gutierrez-Junquera, 5 Sonia Fernandez-Fernandez, 6 Rajitha D Venkatesh, 7 Sandeep K Gupta 8 1 Division of Gastroenterology, Nemours Children's Hospital, Orlando, FL, USA; 2 College of Medicine, University of Central Florida, Orlando, FL, USA; 3 Center for Pharmacogenomics and Translational Research, Nemours Children's Health System, Jacksonville, FL, USA; 4 Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 5 Pediatric Gastroenterology Unit, Hospital Universitario Puerta de Hierro-Majadahonda, Autonomous University of Madrid, Madrid, Spain; 6 Pediatric Gastroenterology Unit, Hospital Universitario Severo Ochoa, Madrid, Spain; 7 Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, OH, USA; 8 Section of Pediatric Gastroenterology, Hepatology and Nutrition, Riley Hospital for Children, Indiana University School of Medicine and Community Health Network, Indianapolis, IN, USA Correspondence: James P Franciosi, Division of Gastroenterology, Nemours Children's Hospital, 6535 Nemours Parkway, Orlando, FL, 32827, USA, Tel +1 407 567 3832 ; +1 407 335 9908, Email Over the past decade, the role of proton pump inhibitor (PPI) medication has evolved from a diagnostic tool for Eosinophilic Esophagitis (EoE), by excluding patients with PPI responsive esophageal eosinophilia (PPI-REE), to a therapy for EoE. This transition resulted from the Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the Appraisal of Guidelines for Research and Evaluation II (AGREE) Conference to support PPI therapy for EoE in children and adults. Additional recent advances have suggested a role for genetic variations that might impact response to PPI therapy for EoE. This review article will explore a brief background of EoE, the evolution of PPI therapy for EoE and its proposed mechanisms, efficacy and safety in children and adults, and considerations for future PPI precision medicine in patients with EoE. Keywords: eosinophilic esophagitis, EoE, proton pump inhibitor medication, PPI, precision medicine EoE is a chronic antigen-mediated inflammatory disease of the esophagus that affects both children and adults (Figure 1). 4 It is a clinicopathologic disorder requiring a constellation of clinical and histologic findings (at least 15 eosinophils/high-powered microscope field (eos/hpf)) to establish the diagnosis, while excluding other etiologies of esophageal eosinophilia. 1 The incidence and prevalence of EoE are rapidly rising as described in several population-based studies from the United States and Europe with an estimated incidence of 6.6 per 100,000 person-years (95% CI, 3–11.7) in children and 7.7 per 100,000 person-years (95% CI, 1.8–17.8) in adults. 5 Esophageal dysfunction in EoE may present differently in children and adults. Infants and young children typically present with feeding difficulty, poor growth, abdominal pain, and vomiting while older children and adults present with dysphagia and esophageal food impaction. Patients with EoE may have a personal history of atopic conditions such as asthma, allergic rhinitis, allergic conjunctivitis and IgE mediated food allergies. Although EoE does not demonstrate classic Mendelian inheritance, there can be a genetic component to the condition in some patients, and a familial history of EoE increases individual risk compared to the general population. 6 Inflammation in EoE is thought to result from penetration of the esophageal mucosa by food or aeroantigens resulting in a T-helper type 2 (T h 2) cellular response and symptoms of esophageal dysfunction. 7 Figure 1 Eosinophilic esophagitis: clinical & pathophysiologic overview. Notes : Top Left: Major known environmental triggers of EoE include most commonly food allergens (ie, dairy, wheat, egg, soy and legumes) and to a lesser extent, aeroallergens (eg, pollen). Recently, a role for the gut microbiome in inception and/or severity of EoE has been proposed. 209 Middle Left: EoE symptoms by age group. Bottom left: The three main classes of EoE therapies: 1.) diet modification, ie, elimination diets; 2.) medications including proton pump inhibitors, topical swallowed corticosteroids, and biologics; 3.) endoscopic dilation. Upper right: EoE pathophysiology current understanding. A breach in the integrity of the esophageal epithelium, potentially facilitated by gastric acid exposure and/or carriage -Abstract Truncated-

Twice Daily PPI Induces Higher Remission Rate in Eosinophilic Esophagitis Than Once Daily Regimen Regardless of Total Daily Dose

Allergic phenotype identified on allergen testing is associated with proton pump inhibitor nonresponse in eosinophilic esophagitis

Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

PPI-amoxicillin Dual Therapy Four Times Daily is Superior to Guidelines Recommended Regimens in the Helicobacter Pylori Eradication Therapy Within Asia: A Systematic Review and Meta-Analysis.

Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions

Acid-suppressive Effects of Rabeprazole: Comparing 10mg and 20mg Twice Daily in Japanese Helicobacter Pylori-Negative and -Positive CYP2C19 Extensive Metabolisers

Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance‐pH parameters implying anti‐reflux mechanism of action

Cost-Effectiveness Analysis of Current Treatment Options for Eosinophilic Esophagitis

Optimized Dual Therapy for Treatment‐naive Patients of Helicobacter Pylori Infection: A Large‐scale Prospective, Multicenter, Open‐label, Randomized Controlled Study

Circulating immunome fingerprint in eosinophilic esophagitis is associated with clinical response to proton pump inhibitor treatment

Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori

Clinical Characteristics and Treatment Outcomes of Patients with Eosinophilic Esophagitis and Eosinophilic Gastroenteritis

Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response

Diminishing Effectiveness of Long-Term Maintenance Topical Steroid Therapy in PPI Non-Responsive Eosinophilic Esophagitis

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan

A Clinical Study of Proton Pump Inhibitor-containing Quadruple Regimen as First-line Therapy for Helicobacter pylori Eradication

The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH

Proton pump inhibitors modulate esophageal epithelial barrier function and crosstalk with eosinophils